Gilder Gagnon Howe & Co’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-333,176	Closed	-$43.8M	–	418
2020 Q4	$43.8M	Sell	333,176 -2,173	-0.6%	-$192K	0.22%	109
2020 Q3	$16.9M	Sell	335,349 -8,640	-3%	-$388K	0.1%	144
2020 Q2	$16.4M	Sell	343,989 -14,045	-4%	-$653K	0.13%	126
2020 Q1	$17.5M	Sell	358,034 -10,630	-3%	-$542K	0.21%	101
2019 Q4	$21.2M	Buy	+368,664	New	+$18.3M	0.22%	99

Gilder Gagnon Howe & Co's EIDX Position: Q1 2021 in Review

Gilder Gagnon Howe & Co sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 333,176 shares — an estimated $43.8M sold.

Gilder Gagnon Howe & Co first reported a position in EIDX in Q4 2019 and held it in 5 quarters. The position peaked at $43.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Gilder Gagnon Howe & Co reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 333,176 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $43.8M.
Gilder Gagnon Howe & Co first reported a position in Eidos Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
Gilder Gagnon Howe & Co's Eidos Therapeutics, Inc. Common Stock position peaked at $43.8M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2021, filed 17 May 2021.